Warbixinta ugu dambeysay ee #WHO ee cudurka qaaxada ayaa shaaca ka qaadaysa xaqiiqo dhab ah: 8.2 milyan oo kiis oo cusub oo cudurka qaaxada ah ayaa la ogaaday sanadkii 2023 - waana tii ugu badnayd tan iyo markii la bilaabay kormeerka caalamiga ah sanadkii 1995. Kororkaan oo ka yimid 7.5 milyan sanadkii 2022 ayaa dib u soo celiyay cudurka qaaxada iyadoo ahdilaaga ugu weyn ee cudurrada faafa, oo ka gudbay COVID-19.
Si kastaba ha ahaatee, dhibaato xitaa ka sii daran ayaa hadhsan soo kabashadan:iska caabbinta jeermiska dila (AMR)WHO waxay saadaalisay in marka la gaaro 2050, AMR ay sheegan kartoilaa 10 milyan oo nolol ah sannadkiiadduunka oo dhan, iyadoo Qaaxada u adkeysata daawada (DR-TB) ay tahay sababta ugu weyn. Sannadkii 2019 oo keliya, AMR waxay si toos ah u dishay 1.3 milyan oo qof—oo ka badan HIV/AIDS iyo duumada oo la isku daray- oo hadda waasababta saddexaad ee ugu badan ee dhimashada adduunka oo dhanHaddii aan faragelin la samayn, dhimashada guud ee ka dhalata AMR waxay gaari kartaa39 milyan marka la gaaro 2050, iyadoo khasaaraha dhaqaale uu kor u kacayo$100 tirilyan.
Sababta Baaritaanka Waqtiga Loogu Sameeyay Aan Laga Wada Xaajoon Karin
Daawaynta qaaxada waxay ku xiran tahay ogaanshaha hore iyo hababka saxda ah ee daawada. Si kastaba ha ahaatee, si xun u isticmaalka antibiyootikada ayaa dardar geliyay qaaxada u adkeysata daawooyinka badan (MDR-TB), taasoo caabuqyada la daweyn karo u rogtay khataro halis ah. Si naxdin leh:
Qaaxada u adkeysata daawada ayaa ah 1/3 dhimashada AMR ee adduunka oo dhan.
Dadka da'da ah waxay wajahayaan dhimashada AMR oo sii kordheysa(kor u kaca 80% tan iyo 1990 dadka waayeelka ah).
Isbeddelka cimiladu wuu dhici karaaFaafidda AMR waxay ka sii daraysaa 2.4% marka la gaaro 2050, oo si aan sinnayn u saameeya gobollada dakhligoodu hooseeyo.
WHO waxay si degdeg ah ugu baaqeysaa in la sameeyo hal-abuur ku saabsan baaritaanno degdeg ah si loola dagaallamo si xun u isticmaalka daroogada iyo in la xiro farqiga daaweynta
Qalabka TB-ga Saddex-geesoodka ah ee CE-Certified ee Macro & Micro-Test: Qalabka Sax ah ee Xilligii AMR
Xalkayagu wuxuu la jaan qaadayaa istaraatiijiyadda xakamaynta AMR ee WHO isagoo awood u siinayaogaanshaha caabuqa qaaxada + rifampicin (RIF) + iska caabbinta isoniazid (INH) isku mar—muhiim u ah xakamaynta DR-TB.
Astaamaha Muhiimka ah:
Xawaaraha iyo SaxnaantaNatiijooyinka 2–2.5 saacadood gudahood iyadoo la adeegsanayo turjumaad otomaatig ah (tababar yar ayaa loo baahan yahay).
Bartilmaameedyo Dhammaystiran:TB: hiddo-wadaha IS6110
iska caabbinta RIF: rpoB (507~533)
Iska caabbinta INH: InhA, AhpC, katG 315
Xasaasiyadda Sare: Waxay ogaataa ugu yaraan 10 bakteeriya/mL (TB) iyo 150–200 bakteeriya/mL calaamadaha iska caabbinta.
WHO-U hoggaansan: Waxay buuxisaa tilmaamaha maaraynta DR-TB.
Iswaafajin Ballaaran: Waxay la shaqeysaa nidaamyada PCR-ga ee waaweyn (tusaale ahaan, Bio-Rad CFX96, SLAN-96P/S).
Sababta Tani Muhiim u tahay:
Aqoonsashada degdegga ah ee hiddo-sidayaasha iska caabbinta waxay ka hortagtaa isticmaalka antibiyootiga ee aan waxtarka lahayn, waxayna yareysaa gudbinta,
Wicitaan Ficil
Isku-darka soo kabashada qaaxada iyo AMR waxay u baahan yihiin qalab isku xidha xawaaraha iyo saxnaanta. Qalabkayagu wuxuu buuxinayaa farqigan - hubinta in daaweyntu si sax ah u bilaabato, markii ugu horreysay.
Baro wax badan:
https://www.mmtest.com/mycobacterium-tuberculosis-nucleic-acid-and-rifampicin%ef%bc%8cisonazid-resistence-product/
Xiriir:marketing@mmtest.com
#IVD #PCR #AMRCrisis #DrugResistance #TB #DHAMMAAD #MDRTB #Baadhista #Caafimaadka Caalamiga ah #WHO #MacroMicroTest
Waqtiga boostada: Noofambar-25-2025